E-selectin Antagonists Protect Hematopoietic Stem Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hematopoietic disorders such as neutropenia, agranulocytosis, and anemia, induced by medical treatments like chemotherapy and radiation, are limited by severe side effects and the need for costly and risky blood transfusions, with existing hematopoietic growth factors being expensive and not fully addressing the issue.

Innovation Solution

The use of E-selectin antagonists, such as small molecules, peptides, or carbohydrate mimetics, that block E-selectin mediated adhesive interactions in the bone marrow, reducing hematopoietic stem cell turnover and protecting these cells from medical treatments, allowing for higher therapeutic doses of chemotherapy or radiation while minimizing side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy or radiation treatment is administered at higher doses to treat cancer, then therapeutic effectiveness is improved, but immunocompromised conditions (neutropenia, agranulocytosis, anemia, thrombocytopenia) worsen due to toxicity on dividing hematopoietic stem cells

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidimmunocompromised conditions

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The E-selectin antagonist is administered before chemotherapy or radiation treatment to preemptively protect hematopoietic stem cells. By blocking E-selectin-mediated adhesion in advance, the stem cells are shielded from the toxic effects of subsequent high-dose treatment, enabling higher therapeutic doses without severe immunocompromised side effects

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The E-selectin antagonist acts as an intermediary substance that blocks the interaction between E-selectin on endothelial cells and its ligands on hematopoietic stem cells. This intermediary action prevents the adhesion that would otherwise lead to stem cell damage from chemotherapy or radiation, allowing high-dose treatment while protecting blood cell production

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If hematopoietic growth factors (G-CSF, GM-CSF, EPO) are used to treat immunocompromised conditions, then blood cell production is stimulated, but treatment cost increases significantly

Engineering Contradiction:

Improveblood cell productionVSAvoidtreatment cost

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The E-selectin antagonist provides a cost-effective alternative to expensive hematopoietic growth factors. By using a single administration of the antagonist to prevent stem cell damage, the need for costly continuous growth factor therapy is reduced, offering an economical approach to maintaining blood cell production during cancer treatment

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

Instead of using expensive growth factors after blood cell depletion occurs, the E-selectin antagonist is administered beforehand to prevent the depletion in the first place. This preventive approach eliminates or reduces the need for subsequent expensive rescue therapy with hematopoietic growth factors

Inventive Principle:

Principle #10Preliminary action

3Reliability

If blood transfusions are used to treat severe immunocompromised conditions, then temporary improvement in blood cell levels is achieved, but risks of infection, fluid overload, and immune-mediated adverse reactions increase

Engineering Contradiction:

Improveblood cell levelsVSAvoidtransfusion risks

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The E-selectin antagonist prevents the development of severe immunocompromised conditions before they require transfusion. By protecting hematopoietic stem cells from chemotherapy or radiation damage in advance, adequate blood cell production is maintained, avoiding the need for risky blood transfusions altogether

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The antagonist enables the patient's own hematopoietic system to maintain adequate blood cell production endogenously during cancer treatment. By blocking E-selectin, the body's stem cells are protected and continue to produce blood cells independently, eliminating the need for external blood transfusions and their associated risks

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

E-selectin antagonists effectively prevent or treat immunocompromised conditions by reducing the impact of medical treatments on hematopoietic stem cells, enabling increased doses of chemotherapy or radiation therapy while minimizing side effects and the need for transfusions.

Implementation Method 1

E-selectin antagonists, such as small molecules, peptides, or carbohydrate mimetics, that block E-selectin mediated adhesive interactions in the bone marrow

Methodology Applied

Scientific EffectAdhesive interactions: Adhesive

Data Source

PatentUS9486497B2Treatment of immunocompromised conditions

Publication Date: 2016.11.08 THE UNIVERSITY OF QUEENSLAND

AI summary

This invention discloses the use of an E-selectin antagonist in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular useful for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.